Tenaya News & Updates

Tenaya in selloff after early-stage data for gene therapy

Tenaya Therapeutics (NASDAQ:TNYA) lost over half its market capitalization on Tuesday after the card...

Dec 17, 2024 • Seeking Alpha

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...

RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-...

Sep 14, 2026 • Markets Insider

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

ASGCT Presentations Include Preclinical Data for TN-401 PKP2 and DWORF Gene Therapy Programs and AAV...

May 03, 2022 • Nasdaq

Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Nov 04, 2022 • Yahoo Finance

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

A fireside chat from the H.C. Wainwright 28th Annual Global Investment Conference will be available ...

Sep 03, 2026 • Markets Insider

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2 ...

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planne...

Apr 27, 2026 • manilatimes

Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TN...

Nov 16, 2022 • Yahoo Finance

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a cl...

May 10, 2023 • Seeking Alpha

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnol...

Apr 28, 2022 • Business Wire

Tenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock Up

TN-401 also holds FDA Orphan Drug and Fast Track designations and European Medicines Agency (EMA) PR...

Sep 14, 2026 • RTTNews

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnol...

May 20, 2022 • Business Wire

Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnol...

Oct 12, 2021 • Nasdaq

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in th...

Nov 06, 2024 • Nasdaq

Alnylam’s research pact worth up to $1.1B sends Tenaya higher

Tenaya Therapeutics (TNYA) added ~10% in the premarket on Thursday after the company signed a resear...

Mar 05, 2026 • Seeking Alpha

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develo...

May 10, 2022 • The Globe and Mail

Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease

Tenaya Therapeutics, Inc. (TNYA) released initial results from its phase 1b/2 MyPEAK-1 study, using ...

Dec 30, 2024 • Seeking Alpha

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Jan 09, 2026 • Yahoo Finance

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday ...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Dec 16, 2024 • Yahoo Finance

Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains

Shares of Bionano Genomics ( BNGO) are surging more than 9% after the company announced that three i...

Sep 14, 2026 • RTTNews

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Nov 10, 2025 • Yahoo Finance

Tenaya Therapeutics Announces RMAT Designation To TN-401

Faraz Ali, CEO of Tenaya Therapeutics, said: "We look forward to sharing additional data from RIDGE-...

Sep 14, 2026 • RTTNews

Tenaya Therapeutics announces orderly board leadership transition

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including ch...

Jan 04, 2026 • The Globe and Mail

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated ...

Tenaya Management to Host Webcast Call for Analysts and Investors on Monday, November 10 at 8:00 a.m...

Nov 08, 2025 • Nasdaq

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNY...

May 07, 2025 • Yahoo Finance

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Aug 04, 2026 • Business Insider

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2...

May 06, 2026 • manilatimes

Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed

Earlier this week, Tenaya Therapeutics reported encouraging interim data from its RIDGE-1 trial of T...

Dec 14, 2025 • Yahoo Finance

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: T...

Mar 02, 2026 • Yahoo Finance

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics (NASDAQ:TNYA) expects to provide regulatory and development updates in the fourt...

Aug 18, 2026 • Yahoo Finance

Tenaya Therapeutics raises $92 million to develop gene therapies and pills for heart disease

Today, the South San Francisco–based start-up Tenaya Therapeutics announced that it raised $92 mil...

Oct 02, 2019 • C&EN